Orexigen® Therapeutics, Inc. ("Orexigen," "we," "our" and "us") is a
biopharmaceutical company focused on the treatment of obesity. Our sole product,
Contrave® (naltrexone HCl / bupropion HCl prolonged release), is approved in the
United States by the U.S. Food and Drug Administration, or FDA, as an adjunct to
a reduced-calorie diet and increased physical activity for chronic weight
management in adults with an initial body mass index, or BMI, of 30 kg/m 2 or
greater (obese), or 27 kg/m 2 or greater (overweight) in the presence of at
least one weight-related comorbid condition. Contrave is a combination of
generic drug components, each of which has already received regulatory approval
for other indications and has been commercialized in the United States and in a
majority of the member countries of the European Union.
In September 2014, the FDA approved our New Drug Application, or NDA, for
Contrave.